for inclusion

[키워드] 1:1 95% CI addition administration Ageusia All participants Analysis Anosmia antibody antibody levels Antibody Response Antibody responses approved assigned AstraZeneca AZD1222 baseline binding antibody booster dose booster doses Brazil category ChAdOx1 ChAdOx1 nCoV-19 Clinical research Coalition control group control vaccine cough COV005 COVID-19 COVID-19 disease COVID-19-related death Cutoff death defined described dose doses double-blind Efficacy Emergency use Endpoint Evidence evidence of exclusion exploratory Exploratory analyses Exploratory analysis Fever finding first dose FIVE Follow-up for inclusion foundation funding geometric mean geometric mean ratio GMR had no Hospital admission immunoassay immunogenicity immunogenicity data independent indicated individual Infection initial Innovation interim analysis ISRCTN89951424 less lower dose Medicine Medicines Medicines and Healthcare products Regulatory Agency Melinda Gate Melinda Gates N protein NAAT NAAT-positive swab network neutralisation NIHR no evidence of nucleic acid nucleic acid amplification nucleic acid amplification test observation offered Older outcomes Oxford pandemic participant phase 2/3 phase 3 study positive swab primary analysis primary endpoint Primary outcome prime-boost interval priming PROTECT pseudovirus randomised controlled Randomised trial Randomly receive receiving recruited regimen Registered regulatory authority response Safety saline placebo SARS-COV-2 infection SARS-CoV-2 N protein second dose secondary Serious Adverse Events seronegative Seven Shortness of breath single-blind Single-dose South South Africa Standard dose subset supported Swab swabs Symptom symptomatic COVID-19 disease symptomatic infection Telle the primary endpoint the timing the vaccine Trial vaccination Vaccine vaccine efficacy Valley Viral Viral particles
[DOI] 10.1016/S0140-6736(21)00432-3 PMC 바로가기 [Article Type] Meta-Analysis